Belgium
ViroVet, founded in 2015 and headquartered in Belgium, is a pioneering player in the Biotechnology and Pharmaceutical industries. The company targets the livestock sector, addressing the pressing challenge of fast-spreading viral diseases. By leveraging a dedicated team of researchers and a robust network of academic and industrial partners, ViroVet is at the forefront of delivering innovative virus control solutions. These advancements are crucial for enhancing the health and economic value of livestock globally.
In its growth journey, ViroVet secured a €6.00M Series B investment on 28 May 2020. This round saw participation from notable investors such as Capricorn Venture Partners, Seventure Partners, PMV, the Agri Investment Fund, Gemma Frisius Fund, Fonds Vives II (University of Louvain, UCL), Biotech Fund Flanders, and KU Leuven. This financial backing underscored investor confidence in ViroVet's potential to transform livestock health management.
